Hepatology:胆汁性肾病引起急性肾衰竭同时伴有集合管中水通道蛋白2表达缺失

2019-01-31 邵玥明,温晓玉 临床肝胆病杂志

肾功能损伤常发生于肝病患者中。肝肾综合征是引起肝硬化患者急性肾损伤(AKI)的重要原因(HRS-AKI,1型)。除此之外,以胆汁性肾病最为常见,其特征是胆管内胆汁管型和胆管损伤。由于胆汁性肾病患者的资料主要来自病例报告或尸检研究,本研究目的是探究胆汁性肾病的发病率和临床过程。

肾功能损伤常发生于肝病患者中。肝肾综合征是引起肝硬化患者急性肾损伤(AKI)的重要原因(HRS-AKI,1型)。除此之外,以胆汁性肾病最为常见,其特征是胆管内胆汁管型和胆管损伤。由于胆汁性肾病患者的资料主要来自病例报告或尸检研究,本研究目的是探究胆汁性肾病的发病率和临床过程。

选取2000年-2016年在肠内科、肝病科或内分泌科住院并接受肾活检的149例患者作为研究对象。其中,79例患者有肝病史和肾功能恶化。

根据最新的EASL标准,79例患者中急性肾损伤45例(57%),慢性肾病34例(43%)。其中45例急性肾损伤患者中肾活检示:8例(17.8%)诊断为胆汁性肾病,而慢性肾病患者均未被诊断为胆汁性肾病。单变量分析发现,血清胆红素、碱性磷酸酶、尿胆红素和尿胆素原可作为诊断胆汁性肾病的预测因素。与胆红素正常的急性肾损伤患者相比,高胆红素血症和胆汁性肾病患者的组织学分析显示,集合管中发生了水通道蛋白2(AQP2)表达缺失。79例患者中的4例发生了需要进行医疗干预的活检相关并发症(5.1%)。

总之,胆汁性肾病常发生于肝病,急性肾损伤和高胆红素患者中。高胆红素血症和胆汁性肾病患者中AQP2的丢失可能是胆汁淤积的毒性作用的结果,并且是肾功能损害的部分原因。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1818978, encodeId=3c6c18189e817, content=<a href='/topic/show?id=b20b98e30e3' target=_blank style='color:#2F92EE;'>#集合管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98730, encryptionId=b20b98e30e3, topicName=集合管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Thu Oct 31 09:55:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809394, encodeId=383b1809394b2, content=<a href='/topic/show?id=5eba834e876' target=_blank style='color:#2F92EE;'>#胆汁性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83478, encryptionId=5eba834e876, topicName=胆汁性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Jul 13 08:55:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299241, encodeId=5ab71299241d8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427290, encodeId=34c0142e29022, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579212, encodeId=41a115e9212e1, content=<a href='/topic/show?id=372b834e673' target=_blank style='color:#2F92EE;'>#胆汁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83476, encryptionId=372b834e673, topicName=胆汁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a0616505872, createdName=108807375_62823132, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359712, encodeId=70e7359e128e, content=不错的作品,为我们探讨研究提供了方针,必须给点个赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Fri Feb 01 07:46:51 CST 2019, time=2019-02-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1818978, encodeId=3c6c18189e817, content=<a href='/topic/show?id=b20b98e30e3' target=_blank style='color:#2F92EE;'>#集合管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98730, encryptionId=b20b98e30e3, topicName=集合管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Thu Oct 31 09:55:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809394, encodeId=383b1809394b2, content=<a href='/topic/show?id=5eba834e876' target=_blank style='color:#2F92EE;'>#胆汁性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83478, encryptionId=5eba834e876, topicName=胆汁性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Jul 13 08:55:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299241, encodeId=5ab71299241d8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427290, encodeId=34c0142e29022, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579212, encodeId=41a115e9212e1, content=<a href='/topic/show?id=372b834e673' target=_blank style='color:#2F92EE;'>#胆汁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83476, encryptionId=372b834e673, topicName=胆汁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a0616505872, createdName=108807375_62823132, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359712, encodeId=70e7359e128e, content=不错的作品,为我们探讨研究提供了方针,必须给点个赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Fri Feb 01 07:46:51 CST 2019, time=2019-02-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1818978, encodeId=3c6c18189e817, content=<a href='/topic/show?id=b20b98e30e3' target=_blank style='color:#2F92EE;'>#集合管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98730, encryptionId=b20b98e30e3, topicName=集合管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Thu Oct 31 09:55:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809394, encodeId=383b1809394b2, content=<a href='/topic/show?id=5eba834e876' target=_blank style='color:#2F92EE;'>#胆汁性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83478, encryptionId=5eba834e876, topicName=胆汁性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Jul 13 08:55:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299241, encodeId=5ab71299241d8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427290, encodeId=34c0142e29022, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579212, encodeId=41a115e9212e1, content=<a href='/topic/show?id=372b834e673' target=_blank style='color:#2F92EE;'>#胆汁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83476, encryptionId=372b834e673, topicName=胆汁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a0616505872, createdName=108807375_62823132, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359712, encodeId=70e7359e128e, content=不错的作品,为我们探讨研究提供了方针,必须给点个赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Fri Feb 01 07:46:51 CST 2019, time=2019-02-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1818978, encodeId=3c6c18189e817, content=<a href='/topic/show?id=b20b98e30e3' target=_blank style='color:#2F92EE;'>#集合管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98730, encryptionId=b20b98e30e3, topicName=集合管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Thu Oct 31 09:55:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809394, encodeId=383b1809394b2, content=<a href='/topic/show?id=5eba834e876' target=_blank style='color:#2F92EE;'>#胆汁性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83478, encryptionId=5eba834e876, topicName=胆汁性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Jul 13 08:55:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299241, encodeId=5ab71299241d8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427290, encodeId=34c0142e29022, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579212, encodeId=41a115e9212e1, content=<a href='/topic/show?id=372b834e673' target=_blank style='color:#2F92EE;'>#胆汁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83476, encryptionId=372b834e673, topicName=胆汁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a0616505872, createdName=108807375_62823132, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359712, encodeId=70e7359e128e, content=不错的作品,为我们探讨研究提供了方针,必须给点个赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Fri Feb 01 07:46:51 CST 2019, time=2019-02-01, status=1, ipAttribution=)]
    2019-02-02 gwc384
  5. [GetPortalCommentsPageByObjectIdResponse(id=1818978, encodeId=3c6c18189e817, content=<a href='/topic/show?id=b20b98e30e3' target=_blank style='color:#2F92EE;'>#集合管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98730, encryptionId=b20b98e30e3, topicName=集合管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Thu Oct 31 09:55:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809394, encodeId=383b1809394b2, content=<a href='/topic/show?id=5eba834e876' target=_blank style='color:#2F92EE;'>#胆汁性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83478, encryptionId=5eba834e876, topicName=胆汁性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Jul 13 08:55:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299241, encodeId=5ab71299241d8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427290, encodeId=34c0142e29022, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579212, encodeId=41a115e9212e1, content=<a href='/topic/show?id=372b834e673' target=_blank style='color:#2F92EE;'>#胆汁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83476, encryptionId=372b834e673, topicName=胆汁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a0616505872, createdName=108807375_62823132, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359712, encodeId=70e7359e128e, content=不错的作品,为我们探讨研究提供了方针,必须给点个赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Fri Feb 01 07:46:51 CST 2019, time=2019-02-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1818978, encodeId=3c6c18189e817, content=<a href='/topic/show?id=b20b98e30e3' target=_blank style='color:#2F92EE;'>#集合管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98730, encryptionId=b20b98e30e3, topicName=集合管)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Thu Oct 31 09:55:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809394, encodeId=383b1809394b2, content=<a href='/topic/show?id=5eba834e876' target=_blank style='color:#2F92EE;'>#胆汁性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83478, encryptionId=5eba834e876, topicName=胆汁性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Jul 13 08:55:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299241, encodeId=5ab71299241d8, content=<a href='/topic/show?id=e7e882e50df' target=_blank style='color:#2F92EE;'>#肾衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82750, encryptionId=e7e882e50df, topicName=肾衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427290, encodeId=34c0142e29022, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579212, encodeId=41a115e9212e1, content=<a href='/topic/show?id=372b834e673' target=_blank style='color:#2F92EE;'>#胆汁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83476, encryptionId=372b834e673, topicName=胆汁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a0616505872, createdName=108807375_62823132, createdTime=Sat Feb 02 14:55:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359712, encodeId=70e7359e128e, content=不错的作品,为我们探讨研究提供了方针,必须给点个赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Fri Feb 01 07:46:51 CST 2019, time=2019-02-01, status=1, ipAttribution=)]
    2019-02-01 lietome24

    不错的作品,为我们探讨研究提供了方针,必须给点个赞了!

    0